LAZANDA

Peak

fentanyl citrate

NDANASALSPRAY, METERED
Approved
Jun 2011
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3

Clinical Trials (3)

NCT00343733Phase 3Completed

Study to Evaluate the Efficacy and Safety of OraVescent Fentanyl Citrate Treatment for the Management of Breakthrough Pain in Opioid-Tolerant Patients With Noncancer-Related Chronic Pain

Started Aug 2006
120 enrolled
Pain
NCT00214942Phase 3Completed

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain

Started Sep 2005
Chronic Low Back Pain
NCT00214955Phase 3Completed

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for the Management of Breakthrough Pain

Started Sep 2005
120 enrolled
Chronic Neuropathic Pain

Loss of Exclusivity

LOE Date
Jan 26, 2032
71 months away
Patent Expiry
Jan 26, 2032

Patent Records (1)

Patent #ExpiryTypeUse Code
9731869
Jan 26, 2032
Product
—
External Resources
DailyMed
Full prescribing information
FDA Drugs@FDA
FDA approval history
RxNorm
Drug nomenclature & identifiers